Literature DB >> 20205671

High PIB retention in Alzheimer's disease is an early event with complex relationship with CSF biomarkers and functional parameters.

A Forsberg1, O Almkvist, H Engler, A Wall, B Långström, A Nordberg.   

Abstract

BACKGROUND: New in vivo amyloid PET imaging tracers, such as (11)C-PIB, provide possibilities to deeper understand the underlying pathological processes in Alzheimer's disease (AD). In this study we investigated how (11)C-PIB retention is related to cerebral glucose metabolism, episodic memory and CSF biomarkers.
METHOD: Thirty-seven patients with mild AD and 21 patients with mild cognitive impairment (MCI) underwent PET examinations with the amyloid tracer (11)C-PIB, (18)F-FDG for measurement of regional cerebral metabolic rate of glucose (rCMRglc), assessment of episodic memory and assay of cerebral spinal fluid (CSF) levels of amyloid-beta (Abeta(1-42)), total tau and phosphorylated tau respectively. Analyses were performed using Statistical Parametric Mapping (SPM) and regions of interest (ROIs).
RESULTS: Pooled data from AD and MCI patients showed strong correlations between (11)C-PIB retention, levels of CSF biomarkers (especially Abeta(1-42)), rCMRglc and episodic memory. Analysis of the MCI group alone revealed significant correlations between (11)C-PIB retention and CSF biomarkers and between CSF biomarkers and episodic memory respectively. A strong correlation was observed in the AD group between rCMRglc and episodic memory as well as a significant correlation between (11)C-PIB retention and rCMRglc in some cortical regions. Regional differences were observed as sign for changes in temporal patterns across brain regions.
CONCLUSIONS: A complex pattern was observed between pathological and functional markers with respect to disease stage (MCI versus AD) and brain regions. Regional differences over time were evident during disease progression. (11)C-PIB PET and CSF Abeta(42) allowed detection of prodromal stages of AD. Amyloid imaging is useful for early diagnosis and evaluation of new therapeutic interventions in AD.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20205671     DOI: 10.2174/156720510790274446

Source DB:  PubMed          Journal:  Curr Alzheimer Res        ISSN: 1567-2050            Impact factor:   3.498


  45 in total

Review 1.  Amyloid imaging as a biomarker for cerebral β-amyloidosis and risk prediction for Alzheimer dementia.

Authors:  William E Klunk
Journal:  Neurobiol Aging       Date:  2011-12       Impact factor: 4.673

2.  Cognitive decline and brain amyloid-β accumulation across 3 years in adults with Down syndrome.

Authors:  Sigan L Hartley; Benjamin L Handen; Darlynne Devenny; Iulia Mihaila; Regina Hardison; Patrick J Lao; William E Klunk; Peter Bulova; Sterling C Johnson; Bradley T Christian
Journal:  Neurobiol Aging       Date:  2017-06-02       Impact factor: 4.673

Review 3.  Progress update: fluid and imaging biomarkers in Alzheimer's disease.

Authors:  Courtney L Sutphen; Anne M Fagan; David M Holtzman
Journal:  Biol Psychiatry       Date:  2013-09-05       Impact factor: 13.382

Review 4.  Current and emerging drug treatment options for Alzheimer's disease: a systematic review.

Authors:  Nathan Herrmann; Sarah A Chau; Ida Kircanski; Krista L Lanctôt
Journal:  Drugs       Date:  2011-10-22       Impact factor: 9.546

5.  Nonlinear Association Between Cerebrospinal Fluid and Florbetapir F-18 β-Amyloid Measures Across the Spectrum of Alzheimer Disease.

Authors:  Jon B Toledo; Maria Bjerke; Xiao Da; Susan M Landau; Norman L Foster; William Jagust; Clifford Jack; Michael Weiner; Christos Davatzikos; Leslie M Shaw; John Q Trojanowski
Journal:  JAMA Neurol       Date:  2015-05       Impact factor: 18.302

6.  CSF biomarker and PIB-PET-derived beta-amyloid signature predicts metabolic, gray matter, and cognitive changes in nondemented subjects.

Authors:  Michael Ewers; Philip Insel; William J Jagust; Leslie Shaw; John Q Trojanowski; Paul Aisen; Ronald C Petersen; Norbert Schuff; Michael W Weiner
Journal:  Cereb Cortex       Date:  2011-10-29       Impact factor: 5.357

Review 7.  Using Pittsburgh Compound B for in vivo PET imaging of fibrillar amyloid-beta.

Authors:  Ann D Cohen; Gil D Rabinovici; Chester A Mathis; William J Jagust; William E Klunk; Milos D Ikonomovic
Journal:  Adv Pharmacol       Date:  2012

8.  Comparing positron emission tomography imaging and cerebrospinal fluid measurements of β-amyloid.

Authors:  Susan M Landau; Ming Lu; Abhinay D Joshi; Michael Pontecorvo; Mark A Mintun; John Q Trojanowski; Leslie M Shaw; William J Jagust
Journal:  Ann Neurol       Date:  2013-12       Impact factor: 10.422

9.  Region-specific hierarchy between atrophy, hypometabolism, and β-amyloid (Aβ) load in Alzheimer's disease dementia.

Authors:  Renaud La Joie; Audrey Perrotin; Louisa Barré; Caroline Hommet; Florence Mézenge; Méziane Ibazizene; Vincent Camus; Ahmed Abbas; Brigitte Landeau; Denis Guilloteau; Vincent de La Sayette; Francis Eustache; Béatrice Desgranges; Gaël Chételat
Journal:  J Neurosci       Date:  2012-11-14       Impact factor: 6.167

10.  In vivo assessment of amyloid-β deposition in nondemented very elderly subjects.

Authors:  Chester A Mathis; Lewis H Kuller; William E Klunk; Beth E Snitz; Julie C Price; Lisa A Weissfeld; Bedda L Rosario; Brian J Lopresti; Judith A Saxton; Howard J Aizenstein; Eric M McDade; M Ilyas Kamboh; Steven T DeKosky; Oscar L Lopez
Journal:  Ann Neurol       Date:  2013-04-17       Impact factor: 10.422

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.